ABSTRACT
Glanzmann thrombasthenia is an inherited bleeding disorder characterized by qualitative or quantitative defects of the platelet-specific integrin, alphaIIbbeta(3). As a result, alphaIIbbeta(3) cannot be activated and cannot bind to fibrinogen, leading to a loss of platelet aggregation. Thrombasthenia is clinically characterized by mucocutaneous hemorrhage with episodes of intracranial and gastrointestinal bleeding. To develop methods for gene therapy of Glanzmann thrombasthenia, a murine leukemia virus (MuLV)-derived vector, -889Pl(A2)beta(3), was transduced into peripheral blood CD34(+) cells from 2 patients with thrombasthenia with defects in the beta(3) gene. The human alphaIIb promoter was used in this vector to drive megakaryocyte-targeted expression of the wild-type beta(3) subunit. Proviral DNA and alphaIIbbeta(3) biosynthesis were detected after in vitro differentiation of transduced thrombasthenic CD34(+) cells with megakaryocyte growth and development factor. Flow cytometric analysis of transduced patient samples indicated that 19% of megakaryocyte progeny expressed alphaIIbbeta(3) on the surface at 34% of normal receptor levels. Treatment of transduced megakaryocytes with a combination of agonists including epinephrine and the thrombin receptor-activating peptide induced the alphaIIbbeta(3) complex to form an activated conformation capable of binding fibrinogen as measured by PAC-1 antibody binding. Transduced cells retracted a fibrin clot in vitro similar to megakaryocytes derived from a normal nonthrombasthenic individual. These results demonstrate ex vivo phenotypic correction of Glanzmann thrombasthenia and support the potential use of hematopoietic CD34(+) cells as targets for alphaIIb promoter-driven MuLV vectors for gene therapy of platelet disorders. (Blood. 2000;95:3645-3651)
Subject(s)
Antigens, CD/genetics , Genetic Therapy , Megakaryocytes/physiology , Platelet Membrane Glycoproteins/genetics , Thrombasthenia/genetics , Thrombasthenia/therapy , Antigens, CD/physiology , Antigens, CD34/blood , Cell Line , Cells, Cultured , Fibrin/metabolism , Flow Cytometry , Humans , Integrin beta3 , Integrins/genetics , Phenotype , Platelet Membrane Glycoproteins/physiology , Polymerase Chain Reaction , Recombinant Proteins/metabolism , Signal Transduction , Thrombasthenia/blood , TransfectionABSTRACT
Megakaryocyte-specific expression of the platelet-adhesion receptor, integrin alphaIIbbeta3, is caused by the presence of regulatory elements of the alphaIIb promoter that direct high-level, selective gene transcription early in megakaryocytopoiesis. To develop methods for targeted expression of transgenes, we transduced human CD34+ peripheral blood cells with a murine leukemia virus (MuLV) vector controlled by the human integrin alphaIIb promoter (nucleotides -889 to +35). A naturally occurring cDNA encoding the Pl(A2) alloantigen form (Pro(33)) of the integrin beta3 subunit was subcloned into this construct (-889Pl(A2)beta3) and transduced into cells that endogenously synthesized Pl(A1)beta3 (Leu(33)) as a marker for detection of provirus-derived beta3. The ability of this vector to target expression of Pl(A2)beta3 to megakaryocytes was first examined in cell lines. Immunoblot analysis with human anti-Pl(A2) alloserum detected synthesis of Pl(A2)beta3 in transduced promegakaryocytic cells; however, Pl(A2)beta3 protein was not detected in transduced epithelial cells. Human hematopoietic CD34+ cells were transduced with -889Pl(A2)beta3 virions and induced to differentiate with megakaryocyte growth and development factor. A hybrid alphaIIbbeta3 complex was formed in progeny megakaryocytes where provirus-derived Pl(A2)beta3 was detected associated with endogenous alphaIIb subunit. Another alphaIIb promoter-driven MuLV vector (-889nlacZ) encoding Escherichia coli beta-galactosidase was used to demonstrate that transgene expression was selectively targeted to the megakaryocyte progeny of transduced CD34+ cells. These studies demonstrate the feasibility of using alphaIIb promoter-driven MuLV vectors for gene transfer of hematopoietic CD34+ cells to target transgene expression in developing megakaryocytes and platelets and indicate potential applications toward human gene therapy for platelet disorders.
Subject(s)
Gene Expression Regulation , Hematopoietic Stem Cells/physiology , Megakaryocytes/physiology , Platelet Glycoprotein GPIIb-IIIa Complex/genetics , Promoter Regions, Genetic , Antigens, CD34/analysis , Cell Line , Genetic Therapy , Genetic Vectors , Hematopoietic Stem Cells/metabolism , Hematopoietic Stem Cells/virology , Humans , Leukemia Virus, Murine , Megakaryocytes/metabolism , Transfection , Transgenes , beta-Galactosidase/geneticsABSTRACT
Future preventive and/or concurrent therapy of neonatal sepsis may require the use of adjuvant immunohematopoietic therapy. In the present study, using reverse transcription-polymerase chain reaction, we demonstrated a significant increase in IL-11 mRNA extracted from the femurs of group B streptococcus (GBS)-infected rats during acute thrombocytopenia (platelet count: 65.8 +/- 19.3 K/mm3, n = 5) compared to that of uninfected neonatal rats (NR) (635.2 +/- 89 K/mm3, n = 5) (174 +/- 17% vs. 100%, p < 0.001, n = 5). We next investigated the prophylactic effect of rhIL-11 on the PLT recovery as well as survival in NR during experimental GBS sepsis. NR received either rhIL-11 (250 micrograms/kg/d) intraperitoneally for 11 d or sham injections before the induction of experimental GBS sepsis. While experimental GBS sepsis resulted in severe thrombocytopenia in control NR, the rhIL-11 pre-treated group had significantly higher PLT counts (24 hr: 417 +/- 50 vs. 221 +/- 54 K/mm3, p < 0.01; 36 hr: 276 +/- 60 vs. 82 +/- 33 K/mm3, p < 0.01; 48 hr: 402 +/- 77 vs. 101 +/- 82 K/mm3, p < 0.05). Administration of rhIL-11 alone also significantly increased the survival rate at 36 and 48 hrs after GBS inoculation compared to the control group (36 hr: 83% vs. 58%, p < 0.05; 48 hr: 50% vs. 18%, p < 0.01, n > or = 30), as did the combination of rhIL-11 with ABS treatment at 36 hrs, compared to the control group (90% vs. 69%, p < 0.05, n > or = 30). These results suggest that endogenous IL-11 gene expression may be upregulated during acute thrombocytopenia and associated bacterial sepsis in NR. This increase in IL-11 gene expression, however, does not appear to prevent severe thrombocytopenia. Furthermore, prophylactic administration of pharmacological doses of rhIL-11 may be potentially beneficial in the management of neonatal GBS sepsis and its associated thrombocytopenia. Future studies are needed to determine the clinical implications of these findings.
Subject(s)
Interleukin-11/metabolism , Sepsis/prevention & control , Streptococcal Infections/prevention & control , Streptococcus agalactiae , Thrombocytopenia/prevention & control , Animals , Gene Expression , Interleukin-11/genetics , Interleukin-11/pharmacology , Platelet Count , Rats , Rats, Sprague-Dawley , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology , Sepsis/blood , Sepsis/complications , Streptococcal Infections/blood , Streptococcal Infections/complications , Thrombocytopenia/blood , Thrombocytopenia/complicationsABSTRACT
Hematopoietic progenitor cells in human umbilical cord blood have been shown to be effective sources for hematopoietic reconstitution following myeloablative therapy. Unfortunately, the use of cord blood (CB) is limited by the number of progenitor cells necessary to reconstitute the older child or adult. We studied the expansion of an isolated population of CD34+ cells from CB and adult bone marrow (ABM) after 1 to 3 weeks in culture when stimulated with lineage-nonspecific (IL-11 and/or SLF) and lineage-specific (G-CSF or GM-CSF) cytokines. IL-11 and SLF alone or in combination did not enhance expansion of CB CD34+ stem cells. With combinations of IL-11, SLF, and G-CSF or GM-CSF, however, after 1, 2, or 3 weeks in culture, WBC expansion was significantly greater in CB vs. ABM (p < 0.05). At all time points, expanded CB consistently demonstrated a significant increase in cell production and myeloid differentiation when compared to ABM. To assess the proliferative potential of the expanded cultures, cells were recovered from the expansion cultures, plated in methylcellulose, and evaluated for CFU-GM and CFU-Meg colony formation. After 2 weeks in culture, a significant increase in CFU-GM colony formation in CB vs. ABM was demonstrated with SLF (p < 0.001), IL-11 plus SLF (p < 0.0005), and IL-11 plus SLF plus G-CSF (p < 0.004). Significantly greater CFU-Meg formation was also seen in CB vs. ABM cells plated after expansion with IL-11 plus SLF plus G-CSF (weeks 1 and 2) or IL-11 plus SLF plus GM-CSF (week 1) (p < 0.05). Finally, immunophenotyping was performed on CB cultures on days 0 and 14, and although a significant reduction of the percentage of progenitors (CD34+/38+/38-/DR+) was seen, their absolute numbers were maintained. (Data for ABM was not available). This study suggests that IL-11, when combined with SLF and more lineage-specific cytokines, can effectively maintain primitive multipotential progenitors and stimulate the differentiation of more committed precursors in CB compared to ABM.
Subject(s)
Bone Marrow Cells , Fetal Blood/cytology , Hematopoietic Stem Cells/cytology , Interleukin-11/pharmacology , Stem Cell Factor/pharmacology , Adult , Antigens, CD34/analysis , Cells, Cultured , Flow Cytometry , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cells/immunology , Humans , Immunophenotyping , Infant, Newborn , Recombinant Proteins/pharmacologyABSTRACT
Umbilical cord blood (CB) has been identified as a potential source of hematopoietic stem cells suitable for clinical transplantation. We used long-term cord blood cultures (LTCBC) to evaluate the hematopoietic potential of populations of umbilical CB cells phenotypically defined and isolated by flow cytometry. LTCBC initiated with CD34+HLA-DR+ and CD34+HLA-DR- CB cells were examined over a period of 8 weeks for the production of assayable burst-forming units-erythroid (BFU-E), colony-forming units-granulocyte/macrophage (CFU-GM), and colony-forming units-mixed (CFU-GEMM) in response to repeated additions of stem cell factor (SCF), interleukin-3 (IL-3), IL-6, and either erythropoietin (Epo) or granulocyte-macrophage colony-stimulating factor (GM-CSF). The LTCBC-initiating cell (LTCBC-IC) appeared to be present among CD34+HLA-DR+ cells, in contrast to our previous findings in adult bone marrow (BM), where the long-term culture initiating cells were shown to be CD34+HLA-DR-. In addition, production of BFU-E, CFU-GM, and CFU-GEMM in CB CD34+HLA-DR+ cells displaying low uptake of the supravital dye rhodamine 123 (Rh123) exceeded those detected in the fraction of cells with high uptake of Rh123. Furthermore, on day 21 of LTCBC, the production of the high proliferative potential colony-forming units (HPP-CFC) by CB CD34+HLA-DR+Rh123dull cells was five-fold greater than that detected in cultures initiated with their Rh123bright counterparts. Collectively, these data show that, contrary to what has been documented in adult human BM, LTCBC-IC and presumably CB cells capable of in vivo engraftment reside in the CD34+HLA-DR+Rh123dull fraction of CB. Although the functional significance of these differences between the in vitro behavior of phenotypically defined populations of CB and BM remains to be determined, these findings constitute an objective parameter with which the suitability of CB for clinical transplantation may be assessed.
Subject(s)
Fetal Blood/cytology , Hematopoiesis , Hematopoietic Stem Cells/cytology , Antigens, CD/analysis , Antigens, CD34 , Bone Marrow Cells , Cell Separation , Cells, Cultured , Erythroid Precursor Cells/cytology , Flow Cytometry , Fluorescent Antibody Technique , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Granulocytes/cytology , HLA-DR Antigens/analysis , Hematopoietic Cell Growth Factors/pharmacology , Humans , Immunomagnetic Separation , Immunophenotyping , Macrophages/cytology , Stem Cell FactorSubject(s)
Antigens, CD/metabolism , Bone Marrow Cells , Bone Marrow/immunology , Immunomagnetic Separation/methods , Antigens, CD34 , Bone Marrow/drug effects , Colony-Forming Units Assay , Culture Media, Conditioned , Erythropoietin/pharmacology , Evaluation Studies as Topic , Flow Cytometry , Fluorescent Antibody Technique , Humans , Immunomagnetic Separation/instrumentation , In Vitro TechniquesABSTRACT
Immunomagnetic separation has been used to enrich CD34-positive cells in umbilical cord blood. Cell purities were increased from 0.59% preseparation to 92.7% postseparation (n = 16) with a mean yield of 75.7%. CFU were enriched 127 fold by immunomagnetic separation. Addition of combinations of recombinant growth factors resulted in cloning efficiencies of greater than 50%.
Subject(s)
Fetal Blood/cytology , Hematopoietic Stem Cells , Immunomagnetic Separation , Antibodies, Monoclonal , Antigens, CD , Antigens, CD34 , Cell Count , Colony-Forming Units Assay , Hematopoietic Cell Growth Factors/pharmacology , Hematopoietic Stem Cells/drug effects , Humans , Immunomagnetic Separation/instrumentation , Immunophenotyping , Infant, Newborn , Stem Cell FactorABSTRACT
Two novel cytokines, stem cell factor (SCF) and PIXY321 (a fusion protein, granulocyte macrophage colony-stimulating factor+IL-3), have recently been demonstrated to enhance in vitro adult myelopoiesis. In this study, we compared the success of separating very early hematopoietic progenitor cells (CD34+) from both cord blood (CB) and adult bone marrow (ABM) and their differential response to SCF, PIXY321, and other later-acting colony-stimulating factors (CSF). Briefly, CD34+ cells were isolated from CB and ABM with an anti-CD34 MAb, HPCA-1, and incubated with various combinations of SCF, PIXY321, and other CSF. The percentage of CD34+ cells was decreased in CB compared to ABM before separation (0.54 versus 1.71%) (p = 0.05). Isolated CD34+ cells from CB and ABM were similar in lineage with respect to CD38, HLA-DR, CD33, and CD5, but decreased in CB with respect to B-lineage expression (CD19, CD10, and CD22) (p = 0.05). SCF increased colony forming unit-granulocyte-macrophage (CFU-GM) formation from CB CD34+ cells compared to unconditioned media and had a significant additive increase with IL-3 (p = 0.006) and granulocyte colony-stimulating factor (p = 0.03). SCF also had an additive increase in CB CFU-GM formation with PIXY321 (p = 0.007). PIXY321 had a similar increase in CFU-GM formation from both CB and ABM CD34+ cells compared to the combination granulocyte macrophage colony-stimulating factor + IL-3. When SCF was added to IL-3, PIXY321, or PIXY321 + IL-6, there was an increase in CFU-GM from CB versus ABM CD34+ cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Cytokines/pharmacology , Fetal Blood/metabolism , Hematopoietic Cell Growth Factors/pharmacology , Hematopoietic Stem Cells/chemistry , Adult , Bone Marrow/drug effects , Bone Marrow/metabolism , Granulocyte-Macrophage Colony-Stimulating Factor/drug effects , Humans , Infant, Newborn , Stem Cell FactorABSTRACT
The ex vivo selective separation of cells from bone marrow and peripheral blood stem cell preparations is increasingly used as an adjunct to hematopoietic rescue following high-dose therapy for refractory cancer. Immunomagnetic separation, in which the target cells are identified using monoclonal antibodies and separated by attachment to paramagnetic particles and passage through a magnetic field, is widely used for both negative and positive cell selection. In this paper, we discuss the factors that should be considered when developing a magnetic separation device for purging tumor cells and selecting stem cells from bone marrow using superparamagnetic microspheres.
Subject(s)
Immunomagnetic Separation , Animals , Cell Count , Humans , Laboratories , Magnetics , Microspheres , Neoplasms/pathology , Neoplasms/therapy , Neoplasms, Experimental/pathology , Neoplasms, Experimental/therapySubject(s)
Antigens, CD , Bone Marrow Cells , Bone Marrow/immunology , Cell Separation/instrumentation , Animals , Antibodies, Monoclonal , Antigens, CD34 , Bone Marrow Purging/instrumentation , Bone Marrow Transplantation , Cattle , Fetal Blood/cytology , Fetal Blood/immunology , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Humans , Infant, Newborn , MagneticsABSTRACT
We have developed a multiassay system consisting of fluorescence microscopy, immunocytology and tumor colony assay to monitor the removal of tumor cells from bone marrow. This system was tested in preclinical purging experiments in which neuroblastoma cells were seeded into bovine marrow and purged by treatment with monoclonal antibodies and immunomagnetic beads. Eight experiments were performed on two different neuroblastoma cell lines seeded at 2% and/or 5% contamination. We consistently demonstrated greater than a 3 log removal with one cycle of antibody/bead treatment and greater than a 1 log further reduction by addition of a second cycle. We also demonstrated removal of all detectable tumor stem cells by this purging method. We feel that this system will prove valuable for monitoring ex vivo tumor removal in future clinical studies and should be considered for use in other purging trials.
Subject(s)
Bone Marrow Purging/methods , Neuroblastoma/therapy , Animals , Antigen-Antibody Reactions , Cattle , Cell Separation , Disease Models, Animal , Humans , Immunoenzyme Techniques , Immunomagnetic Separation , Reference Standards , Tumor Stem Cell AssaySubject(s)
Antibodies, Monoclonal , Bone Marrow Purging/methods , Magnetics , Animals , Bone Marrow Purging/instrumentation , Bone Marrow Transplantation , Cattle , Evaluation Studies as Topic , Humans , In Vitro Techniques , Neuroblastoma/surgery , Tumor Cells, Cultured/cytology , Tumor Cells, Cultured/immunologySubject(s)
Hepatitis A/blood , Hepatitis B/blood , Hepatitis C/blood , Hepatitis, Viral, Human/blood , Interferons/blood , HumansABSTRACT
Monoclonal antibodies have been prepared which are specific for the G1 glycoprotein of La Crosse virus. By competitive radioimmunoassay, 20 IgG-producing clones were found to map in eight antigenic sites; three distinct and five which showed individual patterns of partial competition indicating they may be in close proximity. Unique in situ trypsin cleavage sites on G1 have helped in orienting these defined epitopes relative to the viral membrane. Antibody molecules belonging to one epitope (H) mapped on the trypsin-resistant part of G1 and had negative or extremely low neutralizing and hemagglutination inhibition activities. Seven epitopes were located on the trypsin-sensitive part of G1, a 25,000-Da region which is probably the amino terminus of the protein. Antibodies binding to six of these seven epitopes (A, B, D, E, F, and G) were positive for neutralization and inhibition of hemagglutination, but exhibited a wide range of activities. Epitopes A, F, and G seem to be in an immunodominant region containing the primary site(s) for attachment to cell receptors. Antibody specific for the remaining epitope (C) was unique in that it bound to a site closely adjacent to neutralizing antibody sites, enhanced antibody binding to epitopes A and G, but lacked the capacity to neutralize viral infectivity or inhibit hemagglutination. Enhancement of antibody binding also occurred between two other closely adjacent sites (B and D) and one other distinct epitope (G). In addition, antibody from an IgM-producing clone competed with antibodies to these same four epitopes (B, C, D, and G), indicating they are in close proximity. These data have been used to construct an antigenic map that may now be used as a working model for the study of virus neutralization.